Citations (155)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (18)
Adam T Waickman, Krista Newell, Timothy P Endy & Stephen J Thomas. (2023) Biologics for dengue prevention: up-to-date. Expert Opinion on Biological Therapy 23:1, pages 73-87.
Read now
Read now
Stephen J. Thomas & In-Kyu Yoon. (2019) A review of Dengvaxia®: development to deployment. Human Vaccines & Immunotherapeutics 15:10, pages 2295-2314.
Read now
Read now
Bruno Guy, Fernando Noriega, R. Leon Ochiai, Maïna L’azou, Valentine Delore, Anna Skipetrova, François Verdier, Laurent Coudeville, Stephen Savarino & Nicholas Jackson. (2017) A recombinant live attenuated tetravalent vaccine for the prevention of dengue. Expert Review of Vaccines 16:7, pages 671-684.
Read now
Read now
J. Torresi, G. Ebert & M. Pellegrini. (2017) Vaccines licensed and in clinical trials for the prevention of dengue. Human Vaccines & Immunotherapeutics 13:5, pages 1059-1072.
Read now
Read now
Ian J. Amanna & Mark K. Slifka. (2016) Questions regarding the safety and duration of immunity following live yellow fever vaccination. Expert Review of Vaccines 15:12, pages 1519-1533.
Read now
Read now
Jorge E. Osorio, Derek Wallace & Dan T. Stinchcomb. (2016) A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone. Expert Review of Vaccines 15:4, pages 497-508.
Read now
Read now
Douglas G Widman & Ralph S Baric. (2015) Dengue virus envelope protein domain I/II hinge: a key target for dengue virus vaccine design?. Expert Review of Vaccines 14:1, pages 5-8.
Read now
Read now
Myrna C Bonaldo, Patrícia C Sequeira & Ricardo Galler. (2014) The yellow fever 17D virus as a platform for new live attenuated vaccines. Human Vaccines & Immunotherapeutics 10:5, pages 1256-1265.
Read now
Read now
Ian J Amanna & Mark K Slifka. (2014) Current trends in West Nile virus vaccine development. Expert Review of Vaccines 13:5, pages 589-608.
Read now
Read now
Sai Kit Lam. (2013) Challenges in reducing dengue burden; diagnostics, control measures and vaccines. Expert Review of Vaccines 12:9, pages 995-1010.
Read now
Read now
Anne Tuiskunen Bäck & Åke Lundkvist. (2013) Dengue viruses – an overview. Infection Ecology & Epidemiology 3:1.
Read now
Read now
Monika Simmons, Nimfa Teneza-Mora & Robert Putnak. (2012) Advances in the development of vaccines for dengue fever. Vaccine: Development and Therapy 2, pages 1-14.
Read now
Read now
Mario Lobigs & Michael S Diamond. (2012) Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex. Expert Review of Vaccines 11:2, pages 177-187.
Read now
Read now
Lin H Chen, David R Hill & Annelies Wilder-Smith. (2011) Vaccination of travelers: how far have we come and where are we going?. Expert Review of Vaccines 10:11, pages 1609-1620.
Read now
Read now
Mohan Babu Appaiahgari & Sudhanshu Vrati. (2010) IMOJEV®: a Yellow fever virus-based novel Japanese encephalitis vaccine. Expert Review of Vaccines 9:12, pages 1371-1384.
Read now
Read now
Maria G Guzman, Lisset Hermida, Lidice Bernardo, Rosa Ramirez & Gerardo Guillén. (2010) Domain III of the envelope protein as a dengue vaccine target. Expert Review of Vaccines 9:2, pages 137-147.
Read now
Read now
Anna H Roukens & Leo G Visser. (2008) Yellow fever vaccine: past, present and future. Expert Opinion on Biological Therapy 8:11, pages 1787-1795.
Read now
Read now
Annelies Wilder-Smith & Jacqueline L Deen. (2008) Dengue vaccines for travelers. Expert Review of Vaccines 7:5, pages 569-578.
Read now
Read now
Articles from other publishers (137)
Xiangwei Shi, Kangyixin Sun, You Hu, Qinghan Wang, Guoyang Liao, Li Li, Pengjie Wen, Leo E. Wong, Fan Jia & Fuqiang Xu. (2023) The G285S mutation in nsP1 is sufficient to render Sindbis virus as a stable vector for gene delivery. Frontiers in Microbiology 14.
Crossref
Crossref
Jerome D.G. Comes, Gorben P. Pijlman & Tessy A.H. Hick. (2023) Rise of the RNA machines – self-amplification in mRNA vaccine design. Trends in Biotechnology.
Crossref
Crossref
Vianney Tricou, Brandon Essink, John E. Ervin, Mark Turner, Ian Escudero, Martina Rauscher, Manja Brose, Inge Lefevre, Astrid Borkowski & Derek Wallace. (2023) Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study. PLOS Neglected Tropical Diseases 17:3, pages e0011124.
Crossref
Crossref
J. Erin Staples, Emily H. Davis, Thomas P. Monath & Alan D.T. Barrett. 2023. Plotkin's Vaccines. Plotkin's Vaccines
1251
1321.e19
.
Stephen J. Thomas, Timothy P. Endy & Alan L. Rothman. 2020. Viral Infections of Humans. Viral Infections of Humans
1
65
.
Kerstin Kling, Cristina Domingo, Christian Bogdan, Steven Duffy, Thomas Harder, Jeremy Howick, Jos Kleijnen, Kevin McDermott, Ole Wichmann, Annelies Wilder-Smith & Robert Wolff. (2022) Duration of Protection After Vaccination Against Yellow Fever: A Systematic Review and Meta-Analysis. Clinical Infectious Diseases 75:12, pages 2266-2274.
Crossref
Crossref
Ji Ma, Michael Bright Yakass, Sander Jansen, Bert Malengier-Devlies, Dominique Van Looveren, Lorena Sanchez-Felipe, Thomas Vercruysse, Birgit Weynand, Mahadesh Prasad Arkalagud Javarappa, Osbourne Quaye, Patrick Matthys, Tania Roskams, Johan Neyts, Hendrik Jan Thibaut & Kai Dallmeier. (2022) Live-attenuated YF17D-vectored COVID-19 vaccine protects from lethal yellow fever virus infection in mouse and hamster models. eBioMedicine 83, pages 104240.
Crossref
Crossref
Jessica J. Harrison, Jody Hobson-Peters, Helle Bielefeldt-Ohmann & Roy A. Hall. (2021) Chimeric Vaccines Based on Novel Insect-Specific Flaviviruses. Vaccines 9:11, pages 1230.
Crossref
Crossref
Sophia M. Vrba, Natalie M. Kirk, Morgan E. Brisse, Yuying Liang & Hinh Ly. (2020) Development and Applications of Viral Vectored Vaccines to Combat Zoonotic and Emerging Public Health Threats. Vaccines 8:4, pages 680.
Crossref
Crossref
Josilene Ramos Pinheiro-Michelsen, Rayane da Silva Oliveira Souza, Itana Vivian Rocha Santana, Patrícia de Souza da Silva, Erick Carvalho Mendez, Wilson Barros Luiz & Jaime Henrique Amorim. (2020) Anti-dengue Vaccines: From Development to Clinical Trials. Frontiers in Immunology 11.
Crossref
Crossref
Niraj Mishra, Robbert Boudewijns, Michael Alexander Schmid, Rafael Elias Marques, Sapna Sharma, Johan Neyts & Kai Dallmeier. (2020) A Chimeric Japanese Encephalitis Vaccine Protects against Lethal Yellow Fever Virus Infection without Inducing Neutralizing Antibodies. mBio 11:2.
Crossref
Crossref
Jin Sun, Senyan Du, Zhihang Zheng, Gong Cheng & Xia Jin. (2020) Defeat Dengue and Zika Viruses With a One-Two Punch of Vaccine and Vector Blockade. Frontiers in Microbiology 11.
Crossref
Crossref
Sachin M. Bhagavan. 2020. Dengue Virus Disease. Dengue Virus Disease
37
56
.
Lázaro Gil, Alejandro Martín & Laura Lazo. (2019) Wanted Dead or Alive: A Correlate of Protection Against Dengue Virus. Frontiers in Immunology 10.
Crossref
Crossref
Megan Chesnut, Laura S. Muñoz, Georgina Harris, Dana Freeman, Lucio Gama, Carlos A. Pardo & David Pamies. (2019) In vitro and in silico Models to Study Mosquito-Borne Flavivirus Neuropathogenesis, Prevention, and Treatment. Frontiers in Cellular and Infection Microbiology 9.
Crossref
Crossref
Sourav Kumar Sasmal, Yasuhiro Takeuchi & Shinji Nakaoka. (2019) T-Cell mediated adaptive immunity and antibody-dependent enhancement in secondary dengue infection. Journal of Theoretical Biology 470, pages 50-63.
Crossref
Crossref
Federico Perdomo-Celis, Maria S. Salvato, Sandra Medina-Moreno & Juan C. Zapata. (2019) T-Cell Response to Viral Hemorrhagic Fevers. Vaccines 7:1, pages 11.
Crossref
Crossref
. (2018) Dengue Serostatus and Dengue Vaccine Safety and Efficacy. New England Journal of Medicine 379:20, pages 1968-1969.
Crossref
Crossref
Kathryn B Anderson, Timothy P Endy & Stephen J Thomas. (2018) The dynamic role of dengue cross-reactive immunity: changing the approach to defining vaccine safety and efficacy. The Lancet Infectious Diseases 18:10, pages e333-e338.
Crossref
Crossref
Maïna L’Azou, Jade Assoukpa, Karen Fanouillere, Eric Plennevaux, Matthew Bonaparte, Alain Bouckenooghe, Carina Frago, Fernando Noriega, Betzana Zambrano, R Leon Ochiai, Bruno Guy & Nicholas Jackson. (2018) Dengue seroprevalence: data from the clinical development of a tetravalent dengue vaccine in 14 countries (2005–2014). Transactions of The Royal Society of Tropical Medicine and Hygiene 112:4, pages 158-168.
Crossref
Crossref
J. Erin Staples, Thomas P. Monath, Mark D. Gershman & Alan D.T. Barrett. 2018. Plotkin's Vaccines. Plotkin's Vaccines
1181
1265.e20
.
Scott B Halstead. (2017) Achieving safe, effective, and durable Zika virus vaccines: lessons from dengue. The Lancet Infectious Diseases 17:11, pages e378-e382.
Crossref
Crossref
Birke Andrea Tews & Gregor Meyers. 2017. RNA Vaccines. RNA Vaccines
15
35
.
Scott B. Halstead. (2016) Licensed Dengue Vaccine: Public Health Conundrum and Scientific Challenge. The American Journal of Tropical Medicine and Hygiene 95:4, pages 741-745.
Crossref
Crossref
Sophia Gailhardou, Anna Skipetrova, Gustavo H. Dayan, John Jezorwski, Melanie Saville, Diane Van der Vliet & T. Anh Wartel. (2016) Safety Overview of a Recombinant Live-Attenuated Tetravalent Dengue Vaccine: Pooled Analysis of Data from 18 Clinical Trials. PLOS Neglected Tropical Diseases 10:7, pages e0004821.
Crossref
Crossref
Scott B. Halstead & Maira Aguiar. (2016) Dengue vaccines: Are they safe for travelers?. Travel Medicine and Infectious Disease 14:4, pages 378-383.
Crossref
Crossref
Chukiat Sirivichayakul, Elizabeth A. Barranco-Santana, Inés Esquilin-Rivera, Helen M. L. Oh, Marsha Raanan, Carlos A. Sariol, Lynette P. Shek, Sriluck Simasathien, Mary Kathryn Smith, Ivan Dario Velez, Derek Wallace, Gilad S. Gordon & Dan T. Stinchcomb. (2016) Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study. Journal of Infectious Diseases 213:10, pages 1562-1572.
Crossref
Crossref
Bruno GuyJean LangMelanie SavilleNicholas Jackson. (2016) Vaccination Against Dengue: Challenges and Current Developments. Annual Review of Medicine 67:1, pages 387-404.
Crossref
Crossref
Bryan Paul & Wai Liang Tham. (2016) Controlling Dengue: Effectiveness of Biological Control and Vaccine in Reducing the Prevalence of Dengue Infection in Endemic Areas. Health 08:01, pages 64-74.
Crossref
Crossref
Niyati Khetarpal & Ira Khanna. (2016) Dengue Fever: Causes, Complications, and Vaccine Strategies. Journal of Immunology Research 2016, pages 1-14.
Crossref
Crossref
Huabin Liang, Min Lee & Xia Jin. (2015) Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine. Cellular & Molecular Immunology 13:1, pages 36-46.
Crossref
Crossref
Bruno Guy, Olivier Briand, Jean Lang, Melanie Saville & Nicholas Jackson. (2015) Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward. Vaccine 33:50, pages 7100-7111.
Crossref
Crossref
Renata C. Pereira, Andrea N.M.R. Silva, Marta Cristina O. Souza, Marlon V. Silva, Patrícia P.C.C. Neves, Andrea A.M.V. Silva, Denise D.C.S. Matos, Miguel A.O. Herrera, Anna M.Y. Yamamura, Marcos S. Freire, Luciane P. Gaspar & Elena Caride. (2015) An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures. Vaccine 33:35, pages 4261-4268.
Crossref
Crossref
Gustavo Dayan, Jose L. Arredondo, Gabriel Carrasquilla, Carmen C. Deseda, Reynaldo Dietze, Kleber Luz, Maria Selma N. Costa, Rivaldo V. Cunha, Luis C. Rey, Javier Morales, Humberto Reynales, Maria Miranda, Betzana Zambrano, Enrique Rivas, Pedro Garbes & Fernando Noriega. (2015) Prospective Cohort Study with Active Surveillance for Fever in Four Dengue Endemic Countries in Latin America. The American Journal of Tropical Medicine and Hygiene 93:1, pages 18-23.
Crossref
Crossref
Ilaria Dorigatti, Ricardo Aguas, Christl A. Donnelly, Bruno Guy, Laurent Coudeville, Nicholas Jackson, Melanie Saville & Neil M. Ferguson. (2015) Modelling the immunological response to a tetravalent dengue vaccine from multiple phase-2 trials in Latin America and South East Asia. Vaccine 33:31, pages 3746-3751.
Crossref
Crossref
Andrea K. Erickson & Julie K. Pfeiffer. (2015) Spectrum of disease outcomes in mice infected with YFV-17D. Journal of General Virology 96:6, pages 1328-1339.
Crossref
Crossref
Lauren M. Schwartz, M. Elizabeth Halloran, Anna P. Durbin & Ira M. LonginiJr.Jr.. (2015) The dengue vaccine pipeline: Implications for the future of dengue control. Vaccine 33:29, pages 3293-3298.
Crossref
Crossref
Fabien Aubry, Antoine Nougairède, Ernest A. Gould & Xavier de Lamballerie. (2015) Flavivirus reverse genetic systems, construction techniques and applications: A historical perspective. Antiviral Research 114, pages 67-85.
Crossref
Crossref
Dustin Le, Joseph D. Miller & Vitaly V. Ganusov. (2015) Mathematical modeling provides kinetic details of the human immune response to vaccination. Frontiers in Cellular and Infection Microbiology 4.
Crossref
Crossref
Dwi Hilda Putri, Tjahjani Mirawati Sudiro, Rina Yunita, Ungke Anton Jaya, Beti Ernawati Dewi, Fithriyah Sjatha, Eiji Konishi, Hak Hotta & Pratiwi Sudarmono. (2015) Immunogenicity of a Candidate DNA Vaccine Based on the <i>prM/E</i> Genes of a Dengue Type 2 Virus Cosmopolitan Genotype Strain. Japanese Journal of Infectious Diseases 68:5, pages 357-363.
Crossref
Crossref
A Ghosh & L Dar. (2015) Dengue vaccines: Challenges, development, current status and prospects. Indian Journal of Medical Microbiology 33:1, pages 3-15.
Crossref
Crossref
Jianchun Wei, Hui Chen & Jing An. (2014) Recent progress in dengue vaccine development. Virologica Sinica 29:6, pages 353-363.
Crossref
Crossref
Theodore C. PiersonMichael S. Diamond. (2014) Vaccine Development as a Means to Control Dengue Virus Pathogenesis: Do We Know Enough?. Annual Review of Virology 1:1, pages 375-398.
Crossref
Crossref
Carlos A. Sariol & Laura J. White. (2014) Utility, Limitations, and Future of Non-Human Primates for Dengue Research and Vaccine Development. Frontiers in Immunology 5.
Crossref
Crossref
Stephen J. Thomas. (2014) Developing a dengue vaccine: progress and future challenges. Annals of the New York Academy of Sciences 1323:1, pages 140-159.
Crossref
Crossref
U. THAVARA, A. TAWATSIN & Y. NAGAO. (2013) Simulations to compare efficacies of tetravalent dengue vaccines and mosquito vector control. Epidemiology and Infection 142:6, pages 1245-1258.
Crossref
Crossref
Isabel Delany, Rino Rappuoli & Ennio De Gregorio. (2014) Vaccines for the 21st century. EMBO Molecular Medicine 6:6, pages 708-720.
Crossref
Crossref
Mark K. Slifka. (2014) Vaccine-Mediated Immunity Against Dengue and the Potential for Long-Term Protection Against Disease. Frontiers in Immunology 5.
Crossref
Crossref
Mark K. Slifka & Ian Amanna. (2014) How advances in immunology provide insight into improving vaccine efficacy. Vaccine 32:25, pages 2948-2957.
Crossref
Crossref
Lauren E. Yauch & Sujan Shresta. 2014.
315
372
.
Stephen J. Thomas, Timothy P. Endy & Alan L. Rothman. 2014. Viral Infections of Humans. Viral Infections of Humans
351
381
.
Gustavo H. Dayan, Pedro Garbes, Fernando Noriega, Ana Daniela Izoton de Sadovsky, Patricia Marques Rodrigues, Camila Giuberti & Reynaldo Dietze. (2013) Immunogenicity and Safety of a Recombinant Tetravalent Dengue Vaccine in Children and Adolescents Ages 9–16 Years in Brazil. The American Journal of Tropical Medicine and Hygiene 89:6, pages 1058-1065.
Crossref
Crossref
Amar-Singh HSS, Mia-Tuang Koh, Kah Kee Tan, Lee Gaik Chan, Lynn Zhou, Alain Bouckenooghe, Denis Crevat & Yanee Hutagalung. (2013) Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2?11 years in Malaysia: A randomized, placebo-controlled, Phase III study. Vaccine 31:49, pages 5814-5821.
Crossref
Crossref
Luis Á. Villar, Doris M. Rivera-Medina, José Luis Arredondo-García, Mark Boaz, Linda Starr-Spires, Manoj Thakur, Betzana Zambrano, María C. Miranda, Enrique Rivas & Gustavo H. Dayan. (2013) Safety and Immunogenicity of a Recombinant Tetravalent Dengue Vaccine in 9–16 Year Olds. Pediatric Infectious Disease Journal 32:10, pages 1102-1109.
Crossref
Crossref
A. P. Durbin & S. S. Whitehead. (2013) Response to Ruiz-Alejo et al. Journal of Infectious Diseases 208:7, pages 1184-1184.
Crossref
Crossref
Gustavo H. Dayan, Manoj Thakur, Mark Boaz & Carol Johnson. (2013) Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA. Vaccine 31:44, pages 5047-5054.
Crossref
Crossref
Nicholas G. Reich, Sourya Shrestha, Aaron A. King, Pejman Rohani, Justin Lessler, Siripen Kalayanarooj, In-Kyu Yoon, Robert V. Gibbons, Donald S. Burke & Derek A. T. Cummings. (2013) Interactions between serotypes of dengue highlight epidemiological impact of cross-immunity. Journal of The Royal Society Interface 10:86, pages 20130414.
Crossref
Crossref
Scott B. Halstead. (2013) Identifying protective dengue vaccines: Guide to mastering an empirical process. Vaccine 31:41, pages 4501-4507.
Crossref
Crossref
Alexander A. Rumyantsev, Ana P. Goncalvez, Maryann Giel-Moloney, John Catalan, Yuxi Liu, Qing-sheng Gao, Jeff Almond, Harry Kleanthous & Konstantin V. Pugachev. (2013) Single-dose vaccine against tick-borne encephalitis. Proceedings of the National Academy of Sciences 110:32, pages 13103-13108.
Crossref
Crossref
Anna P. Durbin, Sandra V. Mayer, Shannan L. Rossi, Irma Y. Amaya-Larios, Jose Ramos-Castaneda, Eng Eong Ooi, M. Jane Cardosa, Jorge L. Munoz-Jordan, Robert B. Tesh, William B. Messer, Scott C. Weaver & Nikos Vasilakis. (2013) Emergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity. Virology 439:1, pages 34-41.
Crossref
Crossref
Sathyamangalam Swaminathan, Navin Khanna, Belinda Herring & Suresh Mahalingam. (2013) Dengue vaccine efficacy trial: does interference cause failure?. The Lancet Infectious Diseases 13:3, pages 191-192.
Crossref
Crossref
Rosmari Rodriguez-Roche & Ernest A. Gould. (2013) Understanding the Dengue Viruses and Progress towards Their Control. BioMed Research International 2013, pages 1-20.
Crossref
Crossref
Joshua M. Costin, Elena Zaitseva, Kristen M. Kahle, Cindo O. Nicholson, Dawne K. Rowe, Amanda S. Graham, Lindsey E. Bazzone, Greg Hogancamp, Marielys Figueroa Sierra, Rachel H. Fong, Sung-Tae Yang, Li Lin, James E. Robinson, Benjamin J. Doranz, Leonid V. Chernomordik, Scott F. Michael, John S. Schieffelin & Sharon Isern. (2013) Mechanistic Study of Broadly Neutralizing Human Monoclonal Antibodies against Dengue Virus That Target the Fusion Loop. Journal of Virology 87:1, pages 52-66.
Crossref
Crossref
R.O.S. Soares & A. Caliri. (2013) Stereochemical features of the envelope protein Domain III of dengue virus reveals putative antigenic site in the five-fold symmetry axis. Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics 1834:1, pages 221-230.
Crossref
Crossref
Scott B. Halstead & Stephen J. Thomas. 2013. Vaccines. Vaccines
1042
1051
.
Thomas P. Monath, Mark Gershman, J. Erin Staples & Alan D.T. Barrett. 2013. Vaccines. Vaccines
870
968
.
Claudio F. Lanata, Teresa Andrade, Ana I. Gil, Cynthia Terrones, Omar Valladolid, Betzana Zambrano, Melanie Saville & Denis Crevat. (2012) Immunogenicity and safety of tetravalent dengue vaccine in 2–11 year-olds previously vaccinated against yellow fever: Randomized, controlled, phase II study in Piura, Peru. Vaccine 30:41, pages 5935-5941.
Crossref
Crossref
Hsiang-Chi Lee, Michael Butler & Suh-Chin Wu. (2012) Using recombinant DNA technology for the development of live-attenuated dengue vaccines. Enzyme and Microbial Technology 51:2, pages 67-72.
Crossref
Crossref
P. Dussart, R. Cesaire & A. Sall. (2012) Dengue, fièvre jaune et autres arboviroses. EMC - Maladies infectieuses 9:2, pages 1-24.
Crossref
Crossref
Evandro R. Winkelmann, Douglas G. Widman, Jingya Xia, Tomohiro Ishikawa, Mindy Miller-Kittrell, Michelle H. Nelson, Nigel Bourne, Frank Scholle, Peter W. Mason & Gregg N. Milligan. (2012) Intrinsic adjuvanting of a novel single-cycle flavivirus vaccine in the absence of type I interferon receptor signaling. Vaccine 30:8, pages 1465-1475.
Crossref
Crossref
Filza Sohail, Gazi Mahabubul Alam, Rizwan Rasul Khan & Rahmah Naeem. (2011) How to Cope with Dengue in Developing Countries Like Pakistan?. Asian Journal of Animal and Veterinary Advances 6:12, pages 1094-1124.
Crossref
Crossref
Eiji Konishi & Yuko Miyagawa. (2011) Balance of infection-enhancing and neutralizing antibodies induced by a dengue tetravalent DNA vaccine in a mouse model. Microbes and Infection 13:12-13, pages 1091-1098.
Crossref
Crossref
Scott B. Halstead. 2011. Water and Sanitation‐Related Diseases and the Environment. Water and Sanitation‐Related Diseases and the Environment
111
123
.
David Shaw, Ming Qiao, Anh Wartel-Tram, Remi Forrat & Jean Lang. (2011) Priming Effect of Dengue and Yellow Fever Vaccination on the Immunogenicity, Infectivity, and Safety of a Tetravalent Dengue Vaccine in Humans. The American Journal of Tropical Medicine and Hygiene 85:4, pages 724-731.
Crossref
Crossref
Tomohiro Ishikawa, Gongbo Wang, Douglas G. Widman, Ernesto Infante, Evandro R. Winkelmann, Nigel Bourne & Peter W. Mason. (2011) Enhancing the utility of a prM/E-expressing chimeric vaccine for Japanese encephalitis by addition of the JEV NS1 gene. Vaccine 29:43, pages 7444-7455.
Crossref
Crossref
N. Mantel, Y. Girerd, C. Geny, I. Bernard, J. Pontvianne, J. Lang & V. Barban. (2011) Genetic stability of a dengue vaccine based on chimeric yellow fever/dengue viruses. Vaccine 29:38, pages 6629-6635.
Crossref
Crossref
Bruno Guy, Beatrice Barrere, Claire Malinowski, Melanie Saville, Remy Teyssou & Jean Lang. (2011) From research to phase III: Preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 29:42, pages 7229-7241.
Crossref
Crossref
Anna P. Durbin, Stephen S. Whitehead, Donna Shaffer, Dan Elwood, Kimberli Wanionek, Bhavin Thumar, Joseph E. Blaney, Brian R. Murphy & Alexander C. Schmidt. (2011) A Single Dose of the DENV-1 Candidate Vaccine rDEN1Δ30 Is Strongly Immunogenic and Induces Resistance to a Second Dose in a Randomized Trial. PLoS Neglected Tropical Diseases 5:8, pages e1267.
Crossref
Crossref
K. B. Anderson, R. V. Gibbons, R. Edelman, K. H. Eckels, R. J. Putnak, B. L. Innis & W. Sun. (2011) Interference and Facilitation Between Dengue Serotypes in a Tetravalent Live Dengue Virus Vaccine Candidate. Journal of Infectious Diseases 204:3, pages 442-450.
Crossref
Crossref
Stefan W. Metz & Gorben P. Pijlman. (2011) Arbovirus vaccines; opportunities for the baculovirus-insect cell expression system. Journal of Invertebrate Pathology 107, pages S16-S30.
Crossref
Crossref
Beth-Ann G Coller & David E Clements. (2011) Dengue vaccines: progress and challenges. Current Opinion in Immunology 23:3, pages 391-398.
Crossref
Crossref
Brian R. MurphyStephen S. Whitehead. (2011) Immune Response to Dengue Virus and Prospects for a Vaccine. Annual Review of Immunology 29:1, pages 587-619.
Crossref
Crossref
Iris Valdés, Lázaro Gil, Yaremis Romero, Jorge Castro, Pedro Puente, Laura Lazo, Ernesto Marcos, María G. Guzmán, Gerardo Guillén & Lisset Hermida. (2011) The Chimeric Protein Domain III-Capsid of Dengue Virus Serotype 2 (DEN-2) Successfully Boosts Neutralizing Antibodies Generated in Monkeys upon Infection with DEN-2. Clinical and Vaccine Immunology 18:3, pages 455-459.
Crossref
Crossref
Sarah Murrell, Suh-Chin Wu & Michael Butler. (2011) Review of dengue virus and the development of a vaccine. Biotechnology Advances 29:2, pages 239-247.
Crossref
Crossref
S. J. Thomas. (2011) The Necessity and Quandaries of Dengue Vaccine Development. Journal of Infectious Diseases 203:3, pages 299-303.
Crossref
Crossref
Eiji Konishi. (2011) Issues Related to Recent Dengue Vaccine Development. Tropical Medicine and Health 39:4SUPPLEMENT, pages S63-S71.
Crossref
Crossref
Jorge Poo, Francisco Galan, Remi Forrat, Betzana Zambrano, Jean Lang & Gustavo H. Dayan. (2011) Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City. Pediatric Infectious Disease Journal 30:1, pages e9-e17.
Crossref
Crossref
Charmagne G. Beckett, Jeffrey Tjaden, Timothy Burgess, Janine R. Danko, Cindy Tamminga, Monika Simmons, Shuenn-Jue Wu, Peifang Sun, Tadeusz Kochel, Kanakatte Raviprakash, Curtis G. Hayes & Kevin R. Porter. (2011) Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial. Vaccine 29:5, pages 960-968.
Crossref
Crossref
Qun Zheng, Dongying Fan, Na Gao, Hui Chen, Juan Wang, Ying Ming, Jieqiong Li & Jing An. (2011) Evaluation of a DNA vaccine candidate expressing prM-E-NS1 antigens of dengue virus serotype 1 with or without granulocyte-macrophage colony-stimulating factor (GM-CSF) in immunogenicity and protection. Vaccine 29:4, pages 763-771.
Crossref
Crossref
Danielle Malta Lima, Sérgio Oliveira de Paula, Rafael Freitas de Oliveira França, Patrícia V.B. Palma, Fabiana R. Morais, Alessandra Cristina Gomes-Ruiz, Maria Teresa Prudente de Aquino & Benedito Antonio Lopes da Fonseca. (2011) A DNA vaccine candidate encoding the structural prM/E proteins elicits a strong immune response and protects mice against dengue-4 virus infection. Vaccine 29:4, pages 831-838.
Crossref
Crossref
Thomas P. Monath. 2011. Replicating Vaccines. Replicating Vaccines
349
438
.
Maria G. Guzman, Scott B. Halstead, Harvey Artsob, Philippe Buchy, Jeremy Farrar, Duane J. Gubler, Elizabeth Hunsperger, Axel Kroeger, Harold S. Margolis, Eric Martínez, Michael B. Nathan, Jose Luis Pelegrino, Cameron Simmons, Sutee Yoksan & Rosanna W. Peeling. (2010) Dengue: a continuing global threat. Nature Reviews Microbiology 8:S12, pages S7-S16.
Crossref
Crossref
Dennis Trent, Jinho Shin, Joachim Hombach, Ivana Knezevic & Philip Minor. (2010) WHO Working Group on technical specifications for manufacture and evaluation of dengue vaccines, Geneva, Switzerland, 11–12 May 2009. Vaccine 28:52, pages 8246-8255.
Crossref
Crossref
Joseph Torresi, Karen McCarthy, Emmanuel Feroldi & Claude Méric. (2010) Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials. Vaccine 28:50, pages 7993-8000.
Crossref
Crossref
J. Whitehorn & J. Farrar. (2010) Dengue. British Medical Bulletin 95:1, pages 161-173.
Crossref
Crossref
Samantha Brandler, Claude Ruffie, Valérie Najburg, Marie-Pascale Frenkiel, Hughes Bedouelle, Philippe Desprès & Frédéric Tangy. (2010) Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses. Vaccine 28:41, pages 6730-6739.
Crossref
Crossref
David Franco, Wenjing Li, Fang Qing, Cristina T. Stoyanov, Thomas Moran, Charles M. Rice & David D. Ho. (2010) Evaluation of yellow fever virus 17D strain as a new vector for HIV-1 vaccine development. Vaccine 28:35, pages 5676-5685.
Crossref
Crossref
Cristina T. Stoyanov, Silvia B. Boscardin, Stephanie Deroubaix, Giovanna Barba-Spaeth, David Franco, Ruth S. Nussenzweig, Michel Nussenzweig & Charles M. Rice. (2010) Immunogenicity and protective efficacy of a recombinant yellow fever vaccine against the murine malarial parasite Plasmodium yoelii. Vaccine 28:29, pages 4644-4652.
Crossref
Crossref
Thomas P. Monath, Cynthia K. Lee, Justin G. Julander, Alicja Brown, David W. Beasley, Douglas M. Watts, Edward Hayman, Patrick Guertin, Joseph Makowiecki, Joseph Crowell, Philip Levesque, Gavin C. Bowick, Merribeth Morin, Elizabeth Fowler & Dennis W. Trent. (2010) Inactivated yellow fever 17D vaccine: Development and nonclinical safety, immunogenicity and protective activity. Vaccine 28:22, pages 3827-3840.
Crossref
Crossref
Iris Valdés, Lisset Hermida, Lázaro Gil, Laura Lazo, Jorge Castro, Jorge Martín, Lídice Bernardo, Carlos López, Olivia Niebla, Tamara Menéndez, Yaremis Romero, Jorge Sánchez, María G. Guzmán & Gerardo Guillén. (2010) Heterologous prime-boost strategy in non-human primates combining the infective dengue virus and a recombinant protein in a formulation suitable for human use. International Journal of Infectious Diseases 14:5, pages e377-e383.
Crossref
Crossref
Annelies Wilder-Smith, Eng-Eong Ooi, Subhash G. Vasudevan & Duane J. Gubler. (2010) Update on Dengue: Epidemiology, Virus Evolution, Antiviral Drugs, and Vaccine Development. Current Infectious Disease Reports 12:3, pages 157-164.
Crossref
Crossref
Alexander A. Rumyantsev, Zhen-xi Zhang, Qing-sheng Gao, Nicolas Moretti, Nathan Brown, Harold Kleanthous, Simon Delagrave, Farshad Guirakhoo, Marc S. Collett & Konstantin V. Pugachev. (2010) Direct random insertion of an influenza virus immunologic determinant into the NS1 glycoprotein of a vaccine flavivirus. Virology 396:2, pages 329-338.
Crossref
Crossref
Monika Simmons, Timothy Burgess, Julia Lynch & Robert Putnak. (2010) Protection against dengue virus by non-replicating and live attenuated vaccines used together in a prime boost vaccination strategy. Virology 396:2, pages 280-288.
Crossref
Crossref
Bruno Guy, Farshad Guirakhoo, Veronique Barban, Stephen Higgs, Thomas P. Monath & Jean Lang. (2010) Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 28:3, pages 632-649.
Crossref
Crossref
Joseph E. Blaney, Anna P. Durbin, Brian R. Murphy & Stephen S. Whitehead. 2010. Dengue Virus. Dengue Virus
145
158
.
Anna P. Durbin & Stephen S. Whitehead. 2010. Dengue Virus. Dengue Virus
129
143
.
Rama S. Akondy, Nathan D. Monson, Joseph D. Miller, Srilatha Edupuganti, Dirk Teuwen, Hong Wu, Farah Quyyumi, Seema Garg, John D. Altman, Carlos Del Rio, Harry L. Keyserling, Alexander Ploss, Charles M. Rice, Walter A. Orenstein, Mark J. Mulligan & Rafi Ahmed. (2009) The Yellow Fever Virus Vaccine Induces a Broad and Polyfunctional Human Memory CD8+ T Cell Response. The Journal of Immunology 183:12, pages 7919-7930.
Crossref
Crossref
Stanley A. Plotkin. (2009) Vaccines: the Fourth Century. Clinical and Vaccine Immunology 16:12, pages 1709-1719.
Crossref
Crossref
Daniel P Webster, Jeremy Farrar & Sarah Rowland-Jones. (2009) Progress towards a dengue vaccine. The Lancet Infectious Diseases 9:11, pages 678-687.
Crossref
Crossref
Byron E. E. Martina, Penelope Koraka & Albert D. M. E. Osterhaus. (2009) Dengue Virus Pathogenesis: an Integrated View. Clinical Microbiology Reviews 22:4, pages 564-581.
Crossref
Crossref
Saima Khanam, Rajendra Pilankatta, Navin Khanna & Sathyamangalam Swaminathan. (2009) An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity. Vaccine 27:43, pages 6011-6021.
Crossref
Crossref
Bruno Guy. (2009) Immunogenicity of sanofi pasteur tetravalent dengue vaccine. Journal of Clinical Virology 46, pages S16-S19.
Crossref
Crossref
Pratap Singhasivanon & Julie Jacobson. (2009) Foreword. Journal of Clinical Virology 46, pages S1-S2.
Crossref
Crossref
Natalia S. Pripuzova, Natalia V. Tereshkina, Larissa V. Gmyl, Tatiana I. Dzhivanyan, Alexander A. Rumyantsev, Lidiya Iu. Romanova, Aida N. Mustafina, Vasilii A. Lashkevich & Galina G. Karganova. (2009) Safety evaluation of chimeric Langat/Dengue 4 flavivirus, a live vaccine candidate against tick-borne encephalitis. Journal of Medical Virology 81:10, pages 1777-1785.
Crossref
Crossref
Xia Jin, Olivia Tono Block, Robert Rose & Jacob Schlesinger. (2008) Dengue vaccine development and dengue viral neutralization and enhancement assays. Antiviral Therapy 14:6, pages 739-749.
Crossref
Crossref
John T. Roehrig & Robert S. Lanciotti. 2009. Clinical Virology Manual. Clinical Virology Manual
387
407
.
Grace K Tan & Sylvie Alonso. (2009) Pathogenesis and prevention of dengue virus infection: state-of-the-art. Current Opinion in Infectious Diseases 22:3, pages 302-308.
Crossref
Crossref
Lyle R. Petersen & Alan D. T. Barrett. 2009. Clinical Virology. Clinical Virology
1173
1214
.
Chiou-Feng Lin, Shu-Wen Wan, Mei-Chun Chen, Shin-Chao Lin, Chu-Chen Cheng, Shu-Chen Chiu, Yu-Ling Hsiao, Huan-Yao Lei, Hsiao-Sheng Liu, Trai-Ming Yeh & Yee-Shin Lin. (2008) Liver injury caused by antibodies against dengue virus nonstructural protein 1 in a murine model. Laboratory Investigation 88:10, pages 1079-1089.
Crossref
Crossref
Bruno Guy, Nolwenn Nougarede, Sarah Begue, Violette Sanchez, Nadia Souag, Murielle Carre, Laurent Chambonneau, Dennis N. Morrisson, David Shaw, Ming Qiao, Rafaele Dumas, Jean Lang & Remi Forrat. (2008) Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects. Vaccine 26:45, pages 5712-5721.
Crossref
Crossref
Joseph E. BlaneyJr.Jr., James Speicher, Christopher T. Hanson, Neeraj S. Sathe, Stephen S. Whitehead, Brian R. Murphy & Alexander G. Pletnev. (2008) Evaluation of St. Louis encephalitis virus/dengue virus type 4 antigenic chimeric viruses in mice and rhesus monkeys. Vaccine 26:33, pages 4150-4159.
Crossref
Crossref
Kanakatte Raviprakash, Danher Wang, Dan Ewing, David H. Holman, Karla Block, Jan Woraratanadharm, Lan Chen, Curtis Hayes, John Y. Dong & Kevin Porter. (2008) A Tetravalent Dengue Vaccine Based on a Complex Adenovirus Vector Provides Significant Protection in Rhesus Monkeys against All Four Serotypes of Dengue Virus. Journal of Virology 82:14, pages 6927-6934.
Crossref
Crossref
Ryosuke Suzuki, Rafik Fayzulin, Ilya Frolov & Peter W. Mason. (2008) Identification of Mutated Cyclization Sequences That Permit Efficient Replication of West Nile Virus Genomes: Use in Safer Propagation of a Novel Vaccine Candidate. Journal of Virology 82:14, pages 6942-6951.
Crossref
Crossref
N. Mantel, M. Aguirre, S. Gulia, Y. Girerd-Chambaz, S. Colombani, C. Moste & V. Barban. (2008) Standardized quantitative RT-PCR assays for quantitation of yellow fever and chimeric yellow fever–dengue vaccines. Journal of Virological Methods 151:1, pages 40-46.
Crossref
Crossref
Gisela F. Trindade, Renato S. Marchevsky, Ana M.B. de Fillipis, Rita M.R. Nogueira, Myrna C. Bonaldo, Pedro C. Acero, Elena Caride, Marcos S. Freire & Ricardo Galler. (2008) Limited replication of yellow fever 17DD and 17D-Dengue recombinant viruses in rhesus monkeys. Anais da Academia Brasileira de Ciências 80:2, pages 311-321.
Crossref
Crossref
Tomohiro Ishikawa, Douglas G. Widman, Nigel Bourne, Eiji Konishi & Peter W. Mason. (2008) Construction and evaluation of a chimeric pseudoinfectious virus vaccine to prevent Japanese encephalitis. Vaccine 26:22, pages 2772-2781.
Crossref
Crossref
Charles E. McGee, Mark G. Lewis, Marisa St. Claire, Wendeline Wagner, Jean Lang, Bruno Guy, Konstantin Tsetsarkin, Stephen Higgs & Thierry Decelle. (2008) Recombinant Chimeric Virus with Wild‐Type Dengue 4 Virus Premembrane and Envelope and Virulent Yellow Fever Virus Asibi Backbone Sequences Is Dramatically Attenuated in Nonhuman Primates. The Journal of Infectious Diseases 197:5, pages 693-697.
Crossref
Crossref
Charles E. McGee, Konstantin Tsetsarkin, Dana L. Vanlandingham, Kate L. McElroy, Jean Lang, Bruno Guy, Thierry Decelle & Stephen Higgs. (2008)
Substitution of Wild‐Type Yellow Fever Asibi Sequences for 17D Vaccine Sequencesin ChimeriVax–Dengue 4 Does Not Enhance Infection of
Aedes aegypti
Mosquitoes
. The Journal of Infectious Diseases 197:5, pages 686-692.
Crossref
Crossref
Bruno Guy & Jeffrey W. Almond. (2008) Towards a dengue vaccine: Progress to date and remaining challenges. Comparative Immunology, Microbiology and Infectious Diseases 31:2-3, pages 239-252.
Crossref
Crossref
Douglas G. Widman, Ilya Frolov & Peter W. Mason. 2008.
77
126
.
Scott B. Halstead & David W. Vaughn. 2008. Vaccines. Vaccines
1155
1161
.
Thomas P. Monath, Martin S. Cetron & Dirk E. Teuwen. 2008. Vaccines. Vaccines
959
1055
.
Simon Delagrave & Farshad Guirakhoo. 2008. National Institute of Allergy and Infectious Diseases, NIH. National Institute of Allergy and Infectious Diseases, NIH
459
471
.
Joseph E BlaneyJr.Jr., Neeraj S Sathe, Christopher T Hanson, Cai Yen Firestone, Brian R Murphy & Stephen S Whitehead. (2007) Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Δ30 with those of DEN1. Virology Journal 4:1.
Crossref
Crossref
Robert Edelman. (2007) Dengue Vaccines Approach the Finish Line. Clinical Infectious Diseases 45:Supplement_1, pages S56-S60.
Crossref
Crossref
Stephen S. Whitehead, Joseph E. Blaney, Anna P. Durbin & Brian R. Murphy. (2007) Prospects for a dengue virus vaccine. Nature Reviews Microbiology 5:7, pages 518-528.
Crossref
Crossref
David H. Holman, Danher Wang, Kanakatte Raviprakash, Nicholas U. Raja, Min Luo, Jianghui Zhang, Kevin R. Porter & John Y. Dong. (2007) Two Complex, Adenovirus-Based Vaccines That Together Induce Immune Responses to All Four Dengue Virus Serotypes. Clinical and Vaccine Immunology 14:2, pages 182-189.
Crossref
Crossref